黄杨宁对冠心病心力衰竭患者血浆氮末端脑钠肽水平及运动耐量的影响

目的观察黄杨宁对冠心病心衰患者血浆氮末端脑钠肽前体（NT-proBNP）水平及运动耐量的影响。方法入选冠心病心衰患者112例，随机分为常规治疗组和黄杨宁组，黄杨宁组在常规治疗基础上加用黄杨宁片，2mg·次^-1，3次·d^-1。于开始治疗前及药物治疗6个月后测定NT-proBNP，并行超声·22动图检查和6min步行试验。结果黄杨宁组在治疗后同治疗前及与常规治疗组相比，NT-proBNP水平明显下降（P〈0．05），LVEDV明显缩小，而LVEF显著增加（P〈0．05），6min步行距离显著增加（P〈0．05）。结论黄杨宁可改善冠心病心衰患者运动耐量，有效降低血浆NT-proBNP水平。

Effect of cyclovirobuxine D on plasma N-terminal pro-brain natriuretic peptide level and exercise tolerance in patients with congestive myocardial failure caused by coronary heart disease

Objective To observe the effect of cyclovirobuxine D on plasma N-terminal pro-brain natriuretic peptide （NT-proBNP） level and exercise tolerance in patients with congestive myocardial failure caused by coronary heart disease. Methods A total of 112 patients with congestive myocardial failure caused by coronary heart disease were selected randomly to a cyclovirobuxine D group and a routine therapy group. The level of NT-proBNP, 2-dimensional echo- cardiography （2DE）, and 6-mintute walk distance were measured for all patients at baseline, 6 months after given cyclovirobuxine D, and routine therapy. Results After given cyclovirobuxine D, the levels of NT-proBNP and LVEDV significantly decreased （P〈20.05）, but LVEF increased （P〈0.05）, and the mean distance of 6-minute walk test significantly increased （P〈0.05） in the cyclovirobuxine D group as compared with that of the routine therapy group. Conclusion Cyclovirobuxine D could treat patients with congestive myocardial failure caused by coronary heart disease and significantly attenuate the increase in NT-proBNP.